FDA approves Basaglar, the first “follow-on” insulin glargine product to treat diabetes
16/12/2015
FDA approves Basaglar, the first “follow-on” insulin glargine product to treat diabetes
Leggi
FDA – Interference between Computed Tomography (CT) and Electronic Medical Devices: Notification – Current Understanding of Potential Risk
01/04/2016 http://www.fda.gov/Safety/MedWatch/SafetyInformation/SafetyAlertsforHumanMedicalProducts/ucm493739.htm
Leggi
FDA – Diabetes medications containing Saxagliptin and Alogliptin: Drug safety communication – Risk of heart failure
05/04/2016
FDA – Diabetes medications containing Saxagliptin and Alogliptin: Drug safety communication – Risk of heart failure
Leggi
Standards of Medical Care in Diabetes – 2016
Diabetes Care 2016;39:S4-S5 http://care.diabetesjournals.org/content/39/Supplement_1
Leggi
FDA approves Integra Omnigraft Dermal Regeneration Matrix to treat diabetic foot ulcers.
January 7, 2016 http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm480564.htm
Leggi
FDA – Drug Safety Communication: FDA revises warnings regarding use of the diabetes medicine metformin in certain patients with reduced kidney function
08/04/2016 http://www.fda.gov/Drugs/DrugSafety/ucm493244.htm?source=govdelivery&utm_medium=email&utm_source=govdelivery
Leggi
EMA – Reviews diabetes medicine canagliflozin – Review follows data on toe amputations in ongoing study
15/04/2016
EMA – Reviews diabetes medicine canagliflozin – Review follows data on toe amputations in ongoing study
Leggi
AIFA – Gestione del diabete in gravidanza: nuovo standard di qualità del NICE
27/01/2016 http://www.agenziafarmaco.gov.it/it/content/gestione-del-diabete-gravidanza-nuovo-standard-di-qualit%C3%A0-del-nice
Leggi
EMA – Metformin and metformin-containing medicines – Review of metformin-containing medicines started
01/02/2016 http://www.ema.europa.eu/ema/index.jsp?curl=pages/medicines/human/referrals/Metoformin_and_ metformin-containing_medicines/human_referral_000397.jsp&mid=WC0b01ac05805c516f
Leggi
AIFA – Comunicazione EMA su revisione canaglifozin
15/04/2016
AIFA – Comunicazione EMA su revisione canaglifozin
Leggi